Q2 EPS Estimates for Flora Growth Lowered by Roth Capital

Flora Growth Corp. (NASDAQ:FLGCFree Report) – Equities research analysts at Roth Capital dropped their Q2 2025 earnings per share (EPS) estimates for Flora Growth in a research note issued on Friday, November 15th. Roth Capital analyst W. Kirk now expects that the company will earn $0.02 per share for the quarter, down from their previous estimate of $0.07. The consensus estimate for Flora Growth’s current full-year earnings is ($0.48) per share. Roth Capital also issued estimates for Flora Growth’s Q3 2025 earnings at $0.02 EPS and Q4 2025 earnings at $0.02 EPS.

Separately, Alliance Global Partners reaffirmed a “neutral” rating on shares of Flora Growth in a research note on Thursday, August 15th.

Read Our Latest Analysis on FLGC

Flora Growth Trading Up 9.2 %

FLGC stock opened at $1.31 on Monday. Flora Growth has a twelve month low of $0.70 and a twelve month high of $2.93. The business’s fifty day simple moving average is $1.47 and its two-hundred day simple moving average is $1.22. The company has a current ratio of 1.02, a quick ratio of 0.64 and a debt-to-equity ratio of 0.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Flora Growth stock. XTX Topco Ltd purchased a new position in shares of Flora Growth Corp. (NASDAQ:FLGCFree Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 18,070 shares of the company’s stock, valued at approximately $28,000. XTX Topco Ltd owned approximately 0.14% of Flora Growth at the end of the most recent quarter. Institutional investors own 36.01% of the company’s stock.

Flora Growth Company Profile

(Get Free Report)

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.

Featured Articles

Earnings History and Estimates for Flora Growth (NASDAQ:FLGC)

Receive News & Ratings for Flora Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flora Growth and related companies with MarketBeat.com's FREE daily email newsletter.